Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies

JCI Insight

Volumn 2, Issue 12, 2017, Pages

  Payne, Ruth O ^a   Silk, Sarah E ^a   Elias, Sean C ^a   Milne, Kathryn H ^a   Rawlinson, Thomas A ^a   Llewellyn, David ^a   Shakri, A Rushdi ^b   Jin, Jing ^a   Labbé, Geneviève M ^a   Edwards, Nick J ^a   Poulton, Ian D ^a   Roberts, Rachel ^a   Farid, Ryan ^c   Jørgensen, Thomas ^d   Alanine, Daniel G W ^a   de Cassan, Simone C ^a   Higgins, Matthew K ^e   Otto, Thomas D ^f   McCarthy, James S ^c   de Jongh, Willem A ^d   Nicosia, Alfredo ^g,h,i   Moyle, Sarah ^a   Hill, Adrian V S ^a   Berrie, Eleanor ^a   Chitnis, Chetan E ^b,j   Lawrie, Alison M ^a   Draper, Simon J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^g CEINGE ^*  (Italy)

^h CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j INSTITUT PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85045370878     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/JCI.INSIGHT.93683     Document Type: Article

References (64)

1. Halbroth BR, Draper SJ. Recent developments in malaria vaccinology. Adv Parasitol. 2015;88:1-49.
2. Gething PW, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6(9):e1814.
3. Howes RE, et al. Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis. 2015;9(11):e0004222.
4. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26(1):36-57.
5. Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine technology roadmap. Lancet. 2013;382(9906):1700-1701.
6. Herrera S, et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg. 2011;84(2 Suppl):12-20.
7. Bennett JW, et al. Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy. PLoS Negl Trop Dis. 2016;10(2):e0004423.
8. Vanloubbeeck Y, et al. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine. 2013;31(52):6216-6224.
9. Malkin EM, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005;23(24):3131-3138.
10. Wu Y, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One. 2008;3(7):e2636.
11. Mueller I, Shakri AR, Chitnis CE. Development of vaccines for Plasmodium vivax malaria. Vaccine. 2015;33(52):7489-7495.
12. Tham WH, Healer J, Cowman AF. Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol. 2012;28(1):23-30.
13. Malleret B, et al. Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes. Blood. 2015;125(8):1314-1324.
14. Chitnis CE, Sharma A. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol. 2008;24(1):29-34.
15. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295(6):302-304.
16. Payne RO, Griffin PM, McCarthy JS, Draper SJ. Plasmodium vivax controlled human malaria infection - progress and prospects. Trends Parasitol. 2017;33(2):141-150.
17. Singh AP, Ozwara H, Kocken CH, Puri SK, Thomas AW, Chitnis CE. Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasion. Mol Microbiol. 2005;55(6):1925-1934.
18. Zimmerman PA, Ferreira MU, Howes RE, Mercereau-Puijalon O. Red blood cell polymorphism and susceptibility to Plasmodium vivax. Adv Parasitol. 2013;81:27-76.
19. Tham WH, Beeson JG, Rayner JC. Plasmodium vivax vaccine research - we've only just begun. Int J Parasitol. 2017;47(2-3):111-118.
20. Menard D, et al. Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strains. PLoS Negl Trop Dis. 2013;7(11):e2489.
21. Hester J, et al. De novo assembly of a field isolate genome reveals novel Plasmodium vivax erythrocyte invasion genes. PLoS Negl Trop Dis. 2013;7(12):e2569.
22. Hostetler JB, et al. Independent origin and global distribution of distinct Plasmodium vivax Duffy binding protein gene duplications. PLoS Negl Trop Dis. 2016;10(10):e0005091.
23. Ntumngia FB, Thomson-Luque R, Torres Lde M, Gunalan K, Carvalho LH, Adams JH. A Novel erythrocyte binding protein of Plasmodium vivax suggests an alternate invasion pathway into Duffy-positive reticulocytes. MBio. 2016;7(4):e01261.
24. Batchelor JD, Malpede BM, Omattage NS, DeKoster GT, Henzler-Wildman KA, Tolia NH. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. PLoS Pathog. 2014;10(1):e1003869.
25. Batchelor JD, Zahm JA, Tolia NH. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat Struct Mol Biol. 2011;18(8):908-914.
26. Moreno A, et al. Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques. Vaccine. 2008;26(34):4338-4344.
27. de Cassan SC, et al. Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax. Front Immunol. 2015;6:348.
28. Wiley SR, et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med. 2011;3(93):93ra69.
29. Singh AP, Puri SK, Chitnis CE. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasitol. 2002;121(1):21-31.
30. King CL, et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci USA. 2008;105(24):8363-8368.
31. Nicolete VC, Frischmann S, Barbosa S, King CL, Ferreira MU. Naturally acquired binding-inhibitory antibodies to Plasmodium vivax Duffy binding protein and clinical immunity to malaria in rural Amazonians. J Infect Dis. 2016;214(10):1539-1546.
32. de Cassan SC, Draper SJ. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines. 2013;12(4):365-378.
33. Draper SJ, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008;14(8):819-821.
34. Douglas AD, et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe. 2015;17(1):130-139.
35. O'Hara GA, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012;205(5):772-781.
36. de Barra E, et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One. 2014;9(12):e115161.
37. Sheehy SH, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. MolTher. 2011;19(12):2269-2276.
38. Sheehy SH, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE. 2012;7(2):e31208.
39. Sedegah M, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One. 2011;6(10):e24586.
40. Ewer K, et al. A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA. N Engl J Med. 2016;374(17):1635-1646.
41. Elias SC, et al. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology. 2014;141(4):628-644.
42. Hodgson SH, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther. 2014;22(12):2142-2154.
43. Cole-Tobian JL, et al. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect Immun. 2009;77(9):4009-4017.
44. Ceravolo IP, et al. Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol. 2009;156(3):502-510.
45. Sheehy SH, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20(12):2355-2368.
46. Afolabi MO, et al. Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Mol Ther. 2016;24(8):1470-1477.
47. Green CA, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015;7(300):300ra126.
48. Swadling L, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6(261):261ra153.
49. Gilbert SC. Clinical development of modified vaccinia virus Ankara vaccines. Vaccine. 2013;31(39):4241-4246.
50. Xainli J, Baisor M, Kastens W, Bockarie M, Adams JH, King CL. Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J Immunol. 2002;169(6):3200-3207.
51. Bijker EM, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by pre-erythrocytic immunity. Proc Natl Acad Sci U S A. 2013;110(19):7862-7867.
52. + T cell population with cytotoxic potential. PLoS Negl Trop Dis. 2016;10(12):e0005031.
53. Biswas S, et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One. 2014;9(9):e107903.
54. Tran TM, et al. Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am J Trop Med Hyg. 2005;73(2):244-255.
55. Zakeri S, Babaeekhou L, Mehrizi AA, Abbasi M, Djadid ND. Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission. Am J Trop Med Hyg. 2011;84(6):944-950.
56. Sampath S, et al. Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development. PLoS Pathog. 2013;9(6):e1003420.
57. Kano FS, et al. The presence, persistence and functional properties of Plasmodium vivax Duffy binding protein ii antibodies are influenced by HLA class II allelic variants. PLoS Negl Trop Dis. 2016;10(12):e0005177.
58. Chootong P, et al. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect Immun. 2010;78(3):1089-1095.
59. Chen E, et al. Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy binding protein. Proc Natl Acad Sci U S A. 2016;113(22):6277-6282.
60. Ntumngia FB, et al. Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies. Infect Immun. 2012;80(3):1203-1208.
61. Russell B, et al. A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax. Blood. 2011;118(13):e74-e81.
62. Payne RO, et al. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1/AS01. J Infect Dis. 2016;213(11):1743-1751.
63. Hjerrild KA, et al. Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system. Sci Rep. 2016;6:30357.
64. Shakri AR, Rizvi MM, Chitnis CE. Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein region II. J Immunoassay Immunochem. 2012;33(4):403-413.